Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?
Ignacio Martín-LoechesAntoní TorresPublished in: European respiratory review : an official journal of the European Respiratory Society (2021)
The use of corticosteroids has been considered as a potential alternative co-adjuvant treatment in patients with pneumonia. In patients with COVID-19, the evidence is quite strong and there is a clear benefit of the use of corticosteroids in those patients presenting severe forms of disease.
Keyphrases
- end stage renal disease
- ejection fraction
- coronavirus disease
- sars cov
- newly diagnosed
- chronic kidney disease
- early stage
- prognostic factors
- early onset
- case report
- intensive care unit
- risk assessment
- combination therapy
- replacement therapy
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- respiratory syndrome coronavirus